| Antimicrobial Agent | Susceptibility Profile | Clinical Interpretation |
|---|---|---|
| Amikacin | Sensitive | 4 |
| Aztreonam | Intermediate | 16 |
| Cefepime | Intermediate | 16 |
| Ceftazidime | Sensitive | 8 |
| Ciprofloxacin | Sensitive | <=0.25 |
| Colistin | Sensitive | 2 |
| Doripenem | Resistant | >=8 |
| Gentamicin | Sensitive | 4 |
| Imipenem | Resistant | >=16 |
| Levofloxacin | Sensitive | 1 |
| Meropenem | Resistant | >=16 |
| Piperacillin/Tazobactam | Sensitive | 16 |
| Ticarcillin-clavulanic acid | Intermediate | 64 |
| Resistant Gene Track | Detection Methodology | NCBI Genome Accession |
|---|---|---|
| blaoxa50 | PCR |